Knowledge Intensive Services
Xampla bolsters food and drink expertise with industry hires
Expert creators of drop-in, high performance natural replacements for plastic, Xampla, has further expanded its expert team with two new hires to support the development of its food applications, including spray coatings. ...
Final days to enter Cambridge Independent Science and Technology Awards 2023
There are just days left to get your entry in to the Cambridge Independent Science and Technology Awards 2023. Enter free online by 11pm on January 27 ...
How much do you know about cloud security?
The growth of cloud computing has completely changed the way many of us work. It’s also changed the way we need to think about security. ...
CCDC welcomes new applications for its FAIRE Grants to advance structural science
FAIRE grants provide access to the Cambridge Structural Database, software and training. ...
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia an...
Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, Cécile Matthews, Bhavesh Patel, and Owen Male look at how French payers have valued rarity in the pas...
How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drugs in France in this final article of a three-part series published i...
France’s ATU reform: Early access remains possible, but not all diseases are equal
When France’s ATU reform was implemented, some viewed it as restrictive. In this article published in European Pharmaceutical Review (EPR), Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases. ...
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown. The number of client projects undertaken by CRA consultants in rare diseases now exceeds 600 in the last five years and constitute...
The solution that puts you in charge
2022 has seen a huge drive in businesses and schools going from their traditional landline, to a hosted/cloud, Voice over IP (VoIP) solution. ...